Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Focal Segmental Glomerulosclerosis Clear all

Conditions: Kidney Disease, Chronic
Interventions: BI 764198, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 20
States / cities: Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more

Conditions: Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions: Abatacept, Normal Saline, D5W; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more

Conditions: Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions: Communication; Other
Lead sponsor: University of Michigan; Other
Eligibility: 1 Year to 80 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 16
States / cities: Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more

Conditions: Focal Segmental Glomerulosclerosis
Interventions: Praliciguat (Part A), Placebo (Part A), Praliciguat (Part B); Drug · Other
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 30
States / cities: Chula Vista, California • Garden Grove, California • Los Angeles, California + 26 more

Conditions: Focal Segmental Glomerulosclerosis
Interventions: Adalimumab, Lisinopril, losartan, and atorvastatin, galactose; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 1 Year to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 17
States / cities: Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more

Conditions: Focal Segmental Glomerulosclerosis
Interventions: LIPOSORBER® LA-15; Device
Lead sponsor: Kaneka Medical America LLC; Industry
Eligibility: Up to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 10
States / cities: Loma Linda, California • Wilmington, Delaware • Grand Rapids, Michigan + 5 more

Conditions: Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Interventions: frexalimab, brivekimig, rilzabrutinib, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 15 more

Conditions: FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis
Interventions: Placebo, CCX140-B; Other · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Phoenix, Arizona • Torrance, California • Shreveport, Louisiana + 6 more

Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions: Sparsentan; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more

Conditions: Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy
Interventions: Not listed
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: San Francisco, California • Belmar, New Jersey • Chapel Hill, North Carolina + 1 more

Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions: Kidney Biopsy; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: Up to 80 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2030
U.S. locations: 39
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Conditions: Kidney Diseases, Glomerulosclerosis, Focal Segmental Nephrosis, Lipoid Urologic Disease, Glomerulonephritis, Nephritis, Nephrosis
Interventions: GFB-887; Drug
Lead sponsor: Goldfinch Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Los Angeles, California • Northridge, California • Victorville, California + 14 more

Conditions: Alport Syndrome, Focal Segmental Glomerulosclerosis
Interventions: R3R01; Drug
Lead sponsor: River 3 Renal Corp.; Industry
Eligibility: 12 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 14
States / cities: Los Angeles, California • Boca Raton, Florida • Miami, Florida + 11 more

Conditions: Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Interventions: WAL0921, Placebo; Drug
Lead sponsor: Walden Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more

Conditions: Primary Focal Segmental Glomerulosclerosis
Interventions: Rituximab; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 6 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Chicago, Illinois • Rochester, Minnesota

Conditions: Focal Segmental Glomerulosclerosis
Interventions: RE-021 (Sparsentan), Irbesartan; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 8 Years to 75 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 28
States / cities: San Diego, California • Torrance, California • Denver, Colorado + 19 more

Conditions: Treatment Resistant Nephrotic Syndrome
Interventions: ACTHAR gel; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Focal Glomerulosclerosis
Interventions: Rosiglitazone (Avandia), Adalimumab (Humira); Drug
Lead sponsor: Northwell Health; Other
Eligibility: 2 Years to 40 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: New Hyde Park, New York • Chapel Hill, North Carolina

Conditions: Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
Interventions: Pirfenidone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
Interventions: Bardoxolone methyl capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more

Conditions: Primary Focal Segmental Glomerulosclerosis
Interventions: Obinutuzumab; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
Interventions: Serum and renal tissue analysis; Other
Lead sponsor: Meyer Children's Hospital IRCCS; Other
Eligibility: 0 Years to 99 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Glomerulosclerosis, Focal Segmental
Interventions: Losmapimod; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 8
States / cities: Los Angeles, California • Stanford, California • New Orleans, Louisiana + 5 more

Conditions: Primary Focal Segmental Glomerulosclerosis
Interventions: CXA-10; Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 20 more

Search by objective public record fields.

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NEPTUNE Match Study

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

A Study of CCX140-B in Subjects With FSGS

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)

Nephrotic Syndrome Study Network

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

Study of WAL0921 in Patients With Glomerular Kidney Diseases

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)

Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)

Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

Obinutuzumab in Primary FSGS

SLIT ABS: Study on Patients With Autoimmune Podocytopathy

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)